http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2710797-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a9e6421e9257148abad101e1ce6c162 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2008-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0447ca2e67e2c48c163b3bae4f00ea04 |
| publicationDate | 2009-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2710797-A1 |
| titleOfInvention | Imidazo[1,2-.alpha.]pyridine-2-carboxamide derivatives, preparation thereof and application thereof in therapeutics |
| abstract | Compounds of formula (I) wherein: X and Y form with the nitrogen atom wear them a mono cyclic amine or bicyclic saturated or partially saturated, from 5 to 10 1 to 2 additional heteroatoms selected from O, S, N, optionally substituted by a halogen atom, a group (C1-C6) alkyl, (C1-C6) alkoxy, cyano, NR a Rb, COOR8, the (C1-C6) alkyl and (C1-C6) alkoxy groups being optionally substituted with one or more halogen atoms; R1 represents a hydrogen atom, a halogen atom, a (C1-C6) alkoxy group, a (C1-C6) alkyl group; R2 represents an atom hydrogen, an optionally substituted (C1-C6) alkyl group; a group (C1-C6) optionally substituted alkoxy; a group (C2-C6) alkenyl, a (C2-C6) alkynyl group, a -CO-R5 group, a -CO-NR6R7 group, a group -CO-O-R8, a group -NR9-CO-R10, a group -N = CH-NR a Rb, a halogen atom, a cyano group, nitro, hydroxyiminoalkyl, alkoxyiminoalkyl, a group (C1-C6) alkylthio, a (C1-C6) alkylsulfinyl group, a group (C1-C6) alkylsulfonyl, a (((C1-C6) alkyl) 3) silylethynyl group, a -SO2-NR9R10 group, an optionally substituted phenyl group, a optionally substituted heterocyclic; R3 represents a hydrogen atom, a (C2-C6) alkyl group, a (C1-C6) alkoxy or a halogen atom, R4 represents a hydrogen atom, a (C1-C4) alkyl group, a (C1-C4) alkoxy group or a atom of fluorine, in the basic state or of addition salt to an acid. Use in therapy. |
| priorityDate | 2008-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 550.